A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease
The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).
ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for AD. ELND005 may prevent or inhibit the build up of amyloid protein in the brains of AD patients.
This is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral ELND005 in male and female participants aged 50-85 years with mild to moderate AD. Approximately 340 patients will be enrolled into the study at approximately 65 study sites. Patients will be randomized to receive either ELND005 or placebo. Each patient's participation will last approximately 18 months.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85724, United States
New Haven, Connecticut 06510, United States
Washington D.C., District of Columbia 20057, United States
Tampa, Florida 33617, United States
Indianapolis, Indiana 46202, United States
Kansas City, Kansas 66160, United States
Ann Arbor, Michigan 48109, United States
Pittsburgh, Pennsylvania 15213, United States
Greenville, South Carolina 29615, United States
Bennington, Vermont 05201, United States
Burlington, Vermont 05405, United States
Vancouver, British Columbia V6T 2B5, Canada
London, Ontario N6A 4V2, Canada